Facebook
Twitter
LinkedIn
Forward
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|
Poor responders to common medical weight loss treatments is a challenging situation for clinicians.
|
Treating obesity with bariatric surgery should be thought of as a starting point, not an end point. A key to success after bariatric surgery is the long-term postoperative management.
|
An important part of the Obesity Medicine provider’s practice, and one of the pillars of obesity care, is considering the use of medications for the treatment of overweight and obesity. Anti-obesi
|
Dr. Weber will present and discuss case examples that will increase familiarity with antiobesity medication indications, contraindications, side effect profiles, and medication interactions.
|
Akkermansia muciniphila, a key player in the gut microbiome, has emerged as a significant influencer of GLP-1, a hormone with profound implications for metabolic health.
|
Join us for an informative session designed to enhance your expertise in prescribing GLP1 medications for the treatment of obesity.
|
As the choices available for anti-obesity pharmacotherapy increase, clinicians are faced with options for addressing key clinical scenarios.
|